Alnylam Pharmaceuticals Restricted Investments, Noncurrent remained flat by 0.0% to $22.17M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 67.7%, from $68.59M to $22.17M. Over 5 years (FY 2020 to FY 2025), Restricted Investments, Noncurrent shows a downward trend with a -11.5% CAGR.
An increase may indicate higher regulatory capital requirements or specific collateral obligations, while a decrease suggests a release of restrictions.
These are long-term investments that are legally or contractually restricted from being used for general corporate purpo...
Common in highly regulated financial services firms; peers with similar clearinghouse operations show comparable restricted holdings.
other_restricted_investments_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $40.89M | $40.89M | $40.89M | $40.89M | $49.39M | $49.39M | $49.39M | $49.39M | $49.39M | $49.39M | $49.39M | $49.39M | $49.39M | $68.59M | $68.59M | $68.59M | $68.59M | $51.31M | $22.17M | $22.17M |
| QoQ Change | — | +0.0% | +0.0% | -0.0% | +20.8% | -0.0% | +0.0% | -0.0% | +0.0% | +0.0% | +0.0% | -0.0% | +0.0% | +38.9% | +0.0% | -0.0% | +0.0% | -25.2% | -56.8% | +0.0% |
| YoY Change | — | — | — | — | +20.8% | +20.8% | +20.8% | +20.8% | -0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +38.9% | +38.9% | +38.9% | +38.9% | -25.2% | -67.7% | -67.7% |